SI3159329T1 - Uporaba 2-hidroksi derivatov polinenasičenih maščobnih kislin kot zdravila - Google Patents
Uporaba 2-hidroksi derivatov polinenasičenih maščobnih kislin kot zdravilaInfo
- Publication number
- SI3159329T1 SI3159329T1 SI201032041T SI201032041T SI3159329T1 SI 3159329 T1 SI3159329 T1 SI 3159329T1 SI 201032041 T SI201032041 T SI 201032041T SI 201032041 T SI201032041 T SI 201032041T SI 3159329 T1 SI3159329 T1 SI 3159329T1
- Authority
- SI
- Slovenia
- Prior art keywords
- hidroxyderivates
- medicaments
- fatty acids
- polyunsaturated fatty
- polyunsaturated
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES200900725A ES2345241B1 (es) | 2009-03-16 | 2009-03-16 | Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos. |
| EP16201132.4A EP3159329B1 (en) | 2009-03-16 | 2010-03-15 | Use of 2-hidroxyderivates of polyunsaturated fatty acids as medicaments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3159329T1 true SI3159329T1 (sl) | 2021-01-29 |
Family
ID=42673244
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201032041T SI3159329T1 (sl) | 2009-03-16 | 2010-03-15 | Uporaba 2-hidroksi derivatov polinenasičenih maščobnih kislin kot zdravila |
Country Status (19)
| Country | Link |
|---|---|
| US (7) | US9161928B2 (sl) |
| EP (2) | EP3159329B1 (sl) |
| JP (1) | JP5904592B2 (sl) |
| KR (4) | KR101833772B1 (sl) |
| CN (4) | CN109999018A (sl) |
| AU (6) | AU2010224749B2 (sl) |
| BR (1) | BRPI1009860A8 (sl) |
| CA (1) | CA2754963C (sl) |
| CL (1) | CL2011002268A1 (sl) |
| DK (2) | DK3159329T3 (sl) |
| ES (3) | ES2345241B1 (sl) |
| HK (1) | HK1232207A1 (sl) |
| HU (2) | HUE051850T2 (sl) |
| MX (1) | MX2011009614A (sl) |
| PL (1) | PL2409963T3 (sl) |
| PT (2) | PT2409963T (sl) |
| RU (1) | RU2513995C2 (sl) |
| SI (1) | SI3159329T1 (sl) |
| WO (1) | WO2010106211A1 (sl) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2345241B1 (es) * | 2009-03-16 | 2011-09-08 | Lipopharma Therapeutics | Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos. |
| CA2777827C (en) | 2009-10-30 | 2020-08-18 | Retrotope, Inc. | Alleviating oxidative stress disorders with pufa derivatives |
| KR102020611B1 (ko) | 2011-04-26 | 2019-09-10 | 레트로토프 인코포레이티드 | Ｐｕｆａ와 관련된 신경퇴행성 질환 및 근육 질환 |
| AU2012249921B2 (en) | 2011-04-26 | 2017-06-08 | Biojiva Llc | Oxidative retinal diseases |
| WO2012148929A2 (en) | 2011-04-26 | 2012-11-01 | Retrotope, Inc. | Disorders implicating pufa oxidation |
| KR102020579B1 (ko) | 2011-04-26 | 2019-09-10 | 레트로토프 인코포레이티드 | 에너지 프로세싱 손상 장애 및 미토콘드리아 결함 |
| ES2401629B1 (es) * | 2011-10-07 | 2014-03-04 | Universitat De Les Illes Balears | Enantiómeros de 2-hidroxiderivados de ácidos grasos y su uso como medicamentos. |
| WO2016062746A1 (en) | 2014-10-21 | 2016-04-28 | Universitat De Les Illes Balears | Method for the synthesis of hydroxy-triglycerides and uses thereof for the prevention and treatment of diseases |
| WO2016143703A1 (ja) * | 2015-03-06 | 2016-09-15 | 国立大学法人新潟大学 | レビー小体型認知症のバイオマーカー |
| ES2871130T3 (es) | 2015-11-23 | 2021-10-28 | Retrotope Inc | Marcado isotópico específico del sitio de sistemas de 1, 4-dieno |
| GB201521085D0 (en) * | 2015-11-30 | 2016-01-13 | Biozep As | Use |
| BR112019023944A2 (pt) | 2017-05-16 | 2020-06-09 | Ability Pharmaceuticals S L | combinação farmacêutica para o tratamento de um câncer |
| WO2019157516A1 (en) | 2018-02-12 | 2019-08-15 | resTORbio, Inc. | Combination therapies |
| WO2019241789A1 (en) | 2018-06-15 | 2019-12-19 | Navitor Pharmaceuticals, Inc. | Rapamycin analogs and uses thereof |
| TW202134234A (zh) | 2019-12-05 | 2021-09-16 | 美商奈維特製藥公司 | 雷帕黴素類似物及其用途 |
| BR112022015172A2 (pt) * | 2020-01-29 | 2022-10-11 | Univ Illes Balears | Metabólitos de ácidos graxos alfa-hidroxilados, usos médicos dos mesmos e uso como biomarcadores |
| ES2846824B2 (es) * | 2020-01-29 | 2022-01-19 | Univ Illes Balears | Profarmacos de acidos grasos poliinsaturados y usos medicos de los mismos |
| WO2021160650A1 (en) | 2020-02-10 | 2021-08-19 | Ability Pharmaceuticals S.L. | A pharmaceutical combination for the treatment of a cancer |
| EP4107163A1 (en) | 2020-02-21 | 2022-12-28 | Retrotope, Inc. | Processes for isotopic modification of polyunsaturated fatty acids and derivatives thereof |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8717816D0 (en) | 1987-07-28 | 1987-09-03 | Manchester Inst Science Tech | Fabric testing apparatus |
| GB2218984B (en) * | 1988-05-27 | 1992-09-23 | Renafield Limited | Process for preparing high-concentration mixtures of polyunsaturated fatty acids & their esters and their prophylactic or therapeutic uses |
| JPH05974A (ja) * | 1991-06-21 | 1993-01-08 | Sagami Chem Res Center | ハロゲン化不飽和アルキル化合物及びその前駆体 |
| ES2161146B1 (es) * | 1999-06-29 | 2002-07-01 | Consejo Superior Investigacion | Compuestos antimicrobianos, uso y metodo para inducir resistencia a infecciones de bacterias en plantas. |
| US6344574B1 (en) | 2000-07-20 | 2002-02-05 | The United States Of America As Represented By The Secretary Of Agriculture | Solvent fractionation of chicken fat for making lipid compositions enriched in unsaturated fatty acid-containing triacylglycerols |
| DE10106660A1 (de) * | 2001-02-12 | 2002-08-29 | Celanese Ventures Gmbh | Verfahren zur Herstellung von gamma-Linolensäure aus einer Ciliaten-Kultur durch Zusatz geeigneter Vorläufermoleküle zu dem Kulturmedium |
| ES2186576B1 (es) * | 2001-10-11 | 2004-09-16 | Universitat De Les Illes Balears | Acido 2-hidroxioleico para utilizar como medicamento. |
| PT2022775E (pt) * | 2002-04-01 | 2015-02-04 | Univ Southern California | Eicosanoides trihidroxi polinsaturados |
| US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| CN101102988B (zh) * | 2004-11-19 | 2011-12-14 | 马泰克生物科学公司 | 来自长链多不饱和脂肪酸的氧脂素及其制备和使用方法 |
| GB0428384D0 (en) * | 2004-12-24 | 2005-02-02 | Sla Pharma Ag | Eicosapentaenoic acid |
| US8324276B2 (en) * | 2005-01-24 | 2012-12-04 | Pronova Biopharma Norge As | Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction |
| CN102050720B (zh) | 2005-05-04 | 2013-03-13 | 普罗诺瓦生物医药挪威公司 | 新的dha衍生物及其作为药物的用途 |
| CN101213281B (zh) * | 2005-05-04 | 2013-03-13 | 普罗诺瓦生物医药挪威公司 | 新的dha衍生物及其作为药物的用途 |
| US8059805B2 (en) * | 2005-06-30 | 2011-11-15 | Emc Corporation | Enhanced services provided using communication redirection and processing |
| KR20130101596A (ko) | 2005-07-08 | 2013-09-13 | 마텍 바이오싸이언스스 코포레이션 | 치매 및 치매-전단계와 관련된 용태의 치료를 위한 다중불포화 지방산 |
| EP1772146A1 (en) | 2005-10-03 | 2007-04-11 | Neuropharma, S.A. | Polyunsaturated fatty acids as bace inhibitors |
| WO2007058523A1 (en) * | 2005-11-17 | 2007-05-24 | N.V. Nutricia | Composition with docosapentaenoic acid |
| ATE509624T1 (de) | 2005-12-23 | 2011-06-15 | Nutricia Nv | Zusammensetzung enthaltend mehrfach ungesättigte fettsäuren, proteine, mangan und/oder molybden und nukleotide/nukleoside, zur behandlung von demenz |
| RU2009120568A (ru) | 2006-11-01 | 2010-12-10 | Пронова Биофарма Норге Ас (No) | Композиция |
| CA2667211A1 (en) * | 2006-11-01 | 2008-05-08 | Pronova Biopharma Norge As | Alpha-substituted omega-3 lipids that are activators or modulators of the peroxisome proliferators-activated receptor (ppar) |
| WO2008053340A1 (en) * | 2006-11-03 | 2008-05-08 | Pronova Biopharma Norge As | A combination product comprising at least one lipid substituted in the alpha position and at least one hypoglycemic agent |
| US20080234377A1 (en) * | 2007-03-23 | 2008-09-25 | Martek Biosciences Corporation | Polyunsaturated fatty acids for treatment of dementia and pre-dementia-related conditions |
| ES2345241B1 (es) | 2009-03-16 | 2011-09-08 | Lipopharma Therapeutics | Uso de 2-hidroxiderivados de acidos grasos poliinsaturados como medicamentos. |
| ES2401629B1 (es) * | 2011-10-07 | 2014-03-04 | Universitat De Les Illes Balears | Enantiómeros de 2-hidroxiderivados de ácidos grasos y su uso como medicamentos. |
-
2009
- 2009-03-16 ES ES200900725A patent/ES2345241B1/es active Active
-
2010
- 2010-03-15 WO PCT/ES2010/070153 patent/WO2010106211A1/es active Application Filing
- 2010-03-15 SI SI201032041T patent/SI3159329T1/sl unknown
- 2010-03-15 PT PT107531584T patent/PT2409963T/pt unknown
- 2010-03-15 KR KR1020117024210A patent/KR101833772B1/ko active IP Right Grant
- 2010-03-15 US US13/257,128 patent/US9161928B2/en active Active
- 2010-03-15 AU AU2010224749A patent/AU2010224749B2/en not_active Revoked
- 2010-03-15 CN CN201910095352.2A patent/CN109999018A/zh active Pending
- 2010-03-15 KR KR1020197004239A patent/KR20190018754A/ko active Search and Examination
- 2010-03-15 MX MX2011009614A patent/MX2011009614A/es active IP Right Grant
- 2010-03-15 CN CN2010800119398A patent/CN102356057A/zh active Pending
- 2010-03-15 JP JP2012500281A patent/JP5904592B2/ja active Active
- 2010-03-15 PT PT162011324T patent/PT3159329T/pt unknown
- 2010-03-15 CN CN201610773030.5A patent/CN106420686B/zh active Active
- 2010-03-15 BR BRPI1009860A patent/BRPI1009860A8/pt not_active Application Discontinuation
- 2010-03-15 DK DK16201132.4T patent/DK3159329T3/da active
- 2010-03-15 PL PL10753158T patent/PL2409963T3/pl unknown
- 2010-03-15 HU HUE16201132A patent/HUE051850T2/hu unknown
- 2010-03-15 ES ES16201132T patent/ES2820025T3/es active Active
- 2010-03-15 RU RU2011141850/04A patent/RU2513995C2/ru active
- 2010-03-15 CN CN201610773061.0A patent/CN106349058B/zh active Active
- 2010-03-15 KR KR1020207005917A patent/KR102233102B1/ko active IP Right Grant
- 2010-03-15 CA CA2754963A patent/CA2754963C/en active Active
- 2010-03-15 HU HUE10753158A patent/HUE032027T2/en unknown
- 2010-03-15 ES ES10753158.4T patent/ES2613606T3/es active Active
- 2010-03-15 KR KR1020187005245A patent/KR20180021931A/ko not_active Application Discontinuation
- 2010-03-15 EP EP16201132.4A patent/EP3159329B1/en active Active
- 2010-03-15 EP EP10753158.4A patent/EP2409963B1/en active Active
- 2010-03-15 DK DK10753158.4T patent/DK2409963T3/en active
-
2011
- 2011-09-13 CL CL2011002268A patent/CL2011002268A1/es unknown
-
2015
- 2015-09-29 US US14/869,080 patent/US9763907B2/en active Active
- 2015-09-29 US US14/869,045 patent/US9763906B2/en active Active
-
2016
- 2016-07-13 US US15/209,540 patent/US9907772B2/en active Active
- 2016-10-07 AU AU2016238970A patent/AU2016238970B2/en not_active Revoked
-
2017
- 2017-06-02 HK HK17105487.0A patent/HK1232207A1/zh unknown
- 2017-08-22 US US15/683,379 patent/US10201515B2/en active Active
-
2018
- 2018-06-05 AU AU2018203976A patent/AU2018203976B2/en not_active Expired - Fee Related
- 2018-12-18 US US16/224,262 patent/US20190365690A1/en not_active Abandoned
-
2019
- 2019-09-06 AU AU2019226257A patent/AU2019226257B2/en active Active
-
2020
- 2020-04-22 US US16/855,463 patent/US11253497B2/en active Active
- 2020-07-13 AU AU2020205214A patent/AU2020205214B2/en active Active
- 2020-07-13 AU AU2020205213A patent/AU2020205213B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1232207A1 (zh) | 多不飽和脂肪酸的衍生物作為藥物的用途 | |
| EP2498602A4 (en) | STABILIZED FORMULATIONS FROM FATTY ACIDS | |
| EP2459189A4 (en) | FATTY ACIDS AS ANTI-INFLAMMATORY ACTIVE SUBSTANCES | |
| EP2425007A4 (en) | PREPARATION OF FATTY ACID ESTERS | |
| IL212112A0 (en) | Production of modifird fatty acids in plants | |
| EP2521447A4 (en) | FATTY FATTY ACID DERIVATIVES AND USES THEREOF | |
| EP2483233A4 (en) | HETEROATOMA CONTAINING SUBSTITUTED FATTY ACIDS | |
| ZA201104036B (en) | Fatty acids for use as a medicament | |
| IL232748A0 (en) | Preparations including fatty acids with 20 carbons and methods for their preparation and use | |
| IL214887A0 (en) | Fatty acid monoglyceride compositions | |
| IL213354A (en) | Alpha-monoclonal fatty acid alpha history for use as a drug | |
| PT2528889T (pt) | Processo para preparar e purificar ácidos gordos | |
| GB201304550D0 (en) | Conjugates of polyunsaturated fatty acids and amine-containing compounds and uses thereof | |
| EP2726086A4 (en) | COMPOSITIONS CONTAINING FATTY NITROACIDS | |
| IL219958A0 (en) | Omega-3 fatty acid enriched meat compositions | |
| HK1185806A1 (zh) | 含有多不飽和脂肪酸的組合物 | |
| GB0904300D0 (en) | Essential fatty acid compounds | |
| AU2010903057A0 (en) | Acetylenation of fatty acids | |
| GB201021862D0 (en) | Improvements in the manufacture of fatty acids |